Daratumumab inhibits the progression of CD38-expressing multiple myeloma tumor cells, inducing apoptosis directly through Fc-mediated crosslinking and triggering immune-mediated tumor cell lysis through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis. This evidence concerns the gene CD38 and neoplasm.